Could a common diabetes drug help preemies breathe easier?

NCT ID NCT07120971

Recruiting now Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether metformin, a common diabetes drug, is safe for premature infants with or at risk of bronchopulmonary dysplasia (BPD), a chronic lung disease. The study involves 40 babies split into two groups: older infants already diagnosed with BPD and younger ones at high risk. Researchers will monitor for side effects like low blood sugar and feeding issues, and measure how the drug is processed in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: metformin
What this could lead to: If it works, this could point toward a treatment to reduce lung injury and promote lung growth in premature infants.
What could go wrong: This is a very early safety trial with only 40 infants. It is not designed to prove effectiveness, and metformin may cause side effects like low blood sugar or feeding problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA (BPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHOPULMONARY DYSPLASIA (BPD)

Contacts and locations

Locations

Children's Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.